Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
Scarborough
R M
RM
COR Therapeutics, Inc., South San Francisco, California 94080, USA. rscarborough@corr.com
Gretler
D D
DD
D000284:Administration, Oral; D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000737:chemistry / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D005343:Fibrinolytic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D016023:Integrins / Q000037:antagonists & inhibitors*; D018716:Molecular Mimicry; D010455:Peptides / Q000737:chemistry / Q000302:isolation & purification / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012910:Snake Venoms / Q000737:chemistry
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D016023:Integrins; D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D012910:Snake Venoms